Key points are not available for this paper at this time.
Gambling disorder (GD) is a psychiatric condition associated with both social and family costs; DSM-5 currently includes GD among addictive disorders. Despite the high burden of this condition, to date there are no treatment guidelines approved by Food and Drug Administration (FDA). Purpose of this paper is to offer a qualitative overview about the different pharmacologic agents used for the treatment of GD. Our analysis, conducted on a final selection of 75 scientific papers, demonstrates that a variety of pharmaceutical classes have been utilised, with different results. Published data, although limited by brief duration of the studies and small number of enrolled subjects, shows mixed evidence for serotonergic antidepressants, opioid antagonists, and mood stabilizers. Other compounds, such as glutamatergic agents and psychostimulants, deserve further studies.
Building similarity graph...
Analyzing shared references across papers
Loading...
Matteo Lupi
Giovanni Martinotti
T. Acciavatti
BioMed Research International
Università Cattolica del Sacro Cuore
University of Chieti-Pescara
Building similarity graph...
Analyzing shared references across papers
Loading...
Lupi et al. (Wed,) studied this question.
www.synapsesocial.com/papers/6a12bcf1d61942a939c07344 — DOI: https://doi.org/10.1155/2014/537306
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: